Anzeige
Mehr »
Login
Donnerstag, 27.03.2025 Börsentäglich über 12.000 News von 693 internationalen Medien
"Buy"-Rating und 300 % Kurspotential
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CVW2 | ISIN: US1374041093 | Ticker-Symbol:
NASDAQ
26.03.25
20:39 Uhr
7,440 US-Dollar
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CANDEL THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
CANDEL THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur CANDEL THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiCandel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) ...1
20.03.Candel Therapeutics, Inc. (NASDAQ:CADL) CTO Sells $275,871.96 in Stock7
18.03.Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board 1
17.03.H.C. Wainwright maintains Buy on Candel Therapeutics stock3
15.03.Candel Therapeutics (NASDAQ:CADL) Receives "Buy" Rating from HC Wainwright3
13.03.Candel Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
13.03.Candel Therapeutics, Inc. - 10-K, Annual Report2
CANDEL THERAPEUTICS Aktie jetzt für 0€ handeln
13.03.Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights103Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, localized prostate cancerRecently announced positive final...
► Artikel lesen
13.03.Candel Therapeutics, Inc. - 8-K, Current Report3
25.02.Candel stock plunges 20% following Phase 2 data release13
25.02.Candel Therapeutics stock rises on positive trial data5
25.02.Candel Therapeutics Aktie steigt nach positiven Studiendaten5
25.02.Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer122Positive final survival data after additional follow-up showed notable improvement in estimated median overall survival of 31.4 months after experimental treatment with CAN-2409 versus only 12.5 months...
► Artikel lesen
25.02.Candel Therapeutics, Inc. - 8-K, Current Report1
20.02.Citi sets $25 target on Candel Therapeutics stock with Buy rating15
18.02.Short Interest in Candel Therapeutics, Inc. (NASDAQ:CADL) Decreases By 9.6%7
07.02.Candel initiated at buy by Citi, lead immunotherapy drugs cited9
13.01.Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025276On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025Preparations...
► Artikel lesen
13.01.Candel Therapeutics, Inc. - 8-K, Current Report1
10.01.Candel Therapeutics Interims-CFO Charles Schoch verkauft Aktien im Wert von 81.943 US-Dollar2
Seite:  Weiter >>
58 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1